Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS).
Source: oncologynurseadvisor.com
Stay updated with breaking news from Alicep Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS).
THURSDAY, Sept. 7, 2023 (HealthDay News) -- The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study
The Oncotarget article provides evidence that antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy.